Novel Anti-MRSA Medicinal Compound with Azo-Functionalized Heterocyclic Structure

Description:

This invention introduces a novel medicinal compound based on a heterocyclic system containing azo functionality, synthesized via azo-coupling with 4-amino-benzimidazole. It demonstrates significant efficacy against methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration of 12 µM, coupled with a low cytotoxic profile (IC50 of 47 µM) to mammalian cells. The compound's unique structure provides a new biological activity profile unexplored by prior art, positioning it as a promising candidate for addressing antibiotic resistance.

Key Advantages:

• Potent anti-MRSA activity confirmed at low MIC concentrations.
• Low cytotoxicity to mammalian cells ensuring safety.
• Novel heterocyclic azo-functionalized scaffold with unique biological properties.
• Potential for development of a broad compound library to optimize efficacy.
• Addresses urgent need for new therapies in antibiotic resistance crisis.

Problems Solved:

• Combatting methicillin-resistant Staphylococcus aureus infections.
• Overcoming bacterial antibiotic resistance with novel chemical entities.
• Reduction of toxicity issues commonly associated with antibacterial drugs.
• Lack of effective new MRSA-specific treatments on the market.

Market Applications:

• Development of new anti-MRSA pharmaceutical drugs.
• Use in hospital and clinical settings for resistant bacterial infections.
• Potential licensing or collaboration opportunities with pharmaceutical companies.
• Expansion into broader antibacterial compounds targeting resistant strains.
• Clinical trials and drug development pipelines focused on infectious diseases.